Jerry Keller

Universidad de Alcalá

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

J Cortés-Prieto

Universidad de Alcalá

Pedro L. Valenzuela

Universidad de Alcalá

Francis Lai

A. Nieto

Hospital Universitario Virgen de la Arrixaca

ÓM

Óscar Moralejo Lozano

Complejo Hospitalario Universitario de Toledo

García Díaz

Universidad de Alcalá

Carlos Tacuri

Hospital Universitario Príncipe de Asturias

Juan Carlos Ramos Ramos

Hospital Universitario La Paz

Maria Lina Vicente-Hernanz

Universidad Complutense de Madrid

Aníbal Nieto Díaz

Hospital Universitario Virgen de la Arrixaca

Cooperative Institutions

Universidad de Alcalá

Hospital Universitario Príncipe de Asturias

Universidad Complutense de Madrid

Hospital Universitario La Paz

Hospital Universitario Virgen de la Arrixaca

Universidad de Murcia

Instituto Murciano de Investigación Biosanitaria

Universidad Autónoma de Madrid

Hospital de Cruces

Instituto Nacional de la Salud

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

A Man And A Woman : Un Homme Et Une Femme

Francis Lai Jerry Keller

Source

Cite

Citations (0)

Atypical Endometrial Hyperplasia: Grounds for Possible Misdiagnosis of Endometrial Adenocarcinoma

Gynecologic and Obstetric Investigation (2003)

Pedro L. Valenzuela José Miguel Cuevas Sanz Jerry Keller

Objective: The diagnoses of atypical hyperplasia and well-differentiated adenocarcinoma imply totally different approaches because of clinical and patient-oriented ramifications, especially when morphological differences are not entirely conclusive. The purpose of this study was to examine the relationship between the diagnosis of atypical hyperplasia during curettage or endometrial biopsy and the definitive histological findings from hysterectomy material. Study Design: 23 patients were found fit for the current study and subsequently their clinical histories were reviewed for relevant clinical data, histopathological profiling and type of therapeutic interventions. Results: Adenocarcinoma was observed in 12 (52.17%) of 23 hysterectomy cases. The hyperplasia was found in 10 (43.47%) cases, although 4 of them lacked atypia and 1 case proved to be hyperplasia-free. Conclusion: Hysterectomy was prescribed as the next step in the diagnosis of atypical endometrial hyperplasia. Other wait-and-see approaches could have easily forfeited the chances of providing an adequate treatment for an operable and curable cancer in approximately half of the studied cases.

Atypia

Endometrial hyperplasia

Curettage

Endometrial biopsy

Atypical Hyperplasia

10.1159/000073950

Cite

Citations (34)

A Man and a Woman

Pierre Barouh Claudine Longet Jerry Keller Francis Lai

Source

Cite

Citations (0)

Intrauterine growth retardation: fluctuation of fetal pH measured between beginning and at the completion of labor

Journal of Perinatal Medicine (1994)

Aníbal Nieto Díaz José Villar Roberto Matorras María Serra Pedro L. Valenzuela

The aim of this study was to evaluate the fluctuation of fetal pH in blood samples taken at the beginning of labor and at the moment of birth as related to intrauterine growth retardation syndrome. This is a prospective follow-up of term gestations, of which 41 were diagnosed as intrauterine growth retardation (IUGR) and 61 as normal ones. pH was measured in scalp blood sample at the beginning of the labor and in umbilical artery right after birth in both groups respectively. The rate of decrease of pH value in relation to duration of labor was determined for each case. Our results are: 1) Lower baseline pH were found in the IUGR group (pH 7.32 vs 7.34, p < 0.01), lower arterial blood pH at birth/.23 +/- 0.08 vs 7.27 +/- 0.08, p < 0.05). 2) Faster decrease of the pH during the labor (0.019 unit/hour vs 0.012, p < 0.05) as related to IUGR.IUGR fetuses are more acidotic at the beginning of the labor, and the rate of decrease of the fetal pH per unit of time during the labor is faster at least in a theoretical situation nevertheless it will require more studies if any practical applications are thought of.

Umbilical artery

Growth retardation

10.1515/jpme.1994.22.4.329

Cite

Citations (8)

Changes In Lipid Profile after Biliopancreatic Diversion

Obesity Surgery (2003)

García Díaz Óscar Moralejo Lozano Juan Carlos Ramos Ramos Ma Jesús Gaspar Jerry Keller

Biliopancreatic Diversion

Lipid Profile

Basal (medicine)

Sleeve gastrectomy

10.1381/096089203322509345

Cite

Citations (25)

Long-term follow-up of endometriosis after two different therapies (Gestrinone and Buserelin).

PubMed (1996)

A. Nieto C. Tacuri Maria João Serra Jerry Keller J Cortés-Prieto

To compare the efficacy, tolerance and recurrence rate of endometriosis after 5-year follow-up of treatment with Gestrinone and Buserelin, respectively.A prospective study with randomized follow-up of 5 years duration (minimum) for each patient was done. We included 43 cases of endometriosis diagnosed by laparoscopy or laparotomy and treated them with Gestrinone (Group G, n = 25 cases) or Buserelin intranasal spray (Group B, n = 18) for 6 months.General data: Age, height, weight of patients and AFS score of endometriosis were without significant differences in either group. Specific data: A) Global clinical efficacy was good or excellent in 74% (16/25) of group G and in 78% (14/18) of group B without significant differences. B) Global clinical tolerance was good in 50% of the patients in group G and in 0% in group B (p < 0.001). C) Global evaluation after 5-year follow-up showed "success" only for 36% of patients in group G and in 33% in group B (no significant differences), with "failure" in 40% and 33%, respectively (no significant differences).1) Gestrinone and Buserelin intranasal spray are valid treatments for the remission of endometriosis, with "success", "failure" and "clinical recurrence" rates similar after a follow-up of 5 years of initial treatment. 2) The most significant androgenic effect of Gestrinone was the presence of acne. Vascular effects were also considered as very undesirable effects according to the comments of patients. On the contrary, the effects of analogs are generally better tolerated.

Group B

Group A

Source

Cite

Citations (13)

Hormone replacement therapy: evolution of body mass index, bone mineral density, and lipid profile

Hormone Molecular Biology and Clinical Investigation (2013)

J Cortés-Prieto Maria Lina Vicente-Hernanz Ana Cortés-García Jerry Keller Rosario Cintas del Rio

One hundred and eighty-five female never-hormone users with a mean age of 50.71 (SD = 5.58) years upon initiation of treatment were studied before instauration and during treatment. The profile of patients subjected to the study included body mass index (BMI), bone mineral density (BMD), and lipid profile (LP). In our population, pretreatment values were within the normal range, which is why a hormone replacement therapy (HRT), conjugated equine estrogen plus medroxyprogesterone acetate, was administered to a healthy population of women for 9.82 ± 5.42 years and follow-up comprised 1815.84 woman-years. To study the effects of treatment on the investigated clinical subjects, we resorted to comparative analyses of pretreatment and posttreatment mean values: descriptive and comparative hypothesis, followed by a repeated measurements design to investigate the evolution on three levels according to age groups just before the initiation of the treatment and on the other three levels during the treatment with a minimum follow-up of 9 years. On the basis of the numerical results, we were able to conclude that BMD decreased significantly (p = 0.00) well above the values found on curves corresponding to these age groups. The total cholesterol decreased significantly at 2-3 years interval (p = 0.04). The rest of the LP factors remained within a safe margin. Therefore, long-term HRT may be considered initially as a beneficial alternative in the treated study population.

Lipid Profile

Medroxyprogesterone

Hormone Therapy

10.1515/hmbci-2013-0002

Cite

Citations (3)

Evaluation of Gestrinone after Surgery in Treatment of Endometriosis

Gynecologic and Obstetric Investigation (1997)

A. Nieto Carlos Tacuri María Helena Lima Gusmão Sena Jerry Keller J Cortés-Prieto

Objective: The clinical and histological efficacy of gestrinone in the treatment of endometriosis was evaluated. Methods: A prospective study was performed with longitudinal follow-up of 4 years duration (minimum) for each patient. Twenty-five cases of endometriosis were treated with gestrinone (as a drug of choice or associated with other local surgical treatment) during 6 months. Results: The total or partial response to pain was induced with treatment in 19 of the 20 cases (95%), and posttreatment pregnancies were induced in 3 of the 9 cases of infertility (33.3%). The global clinical efficacy was as follows: none (n = 5,20%), poor (n = 2, 8%), moderate (n = 2, 8%), good (n = 3, 12%) and excellent (n = 13, 52%). The pretreatment American Fertility Society score was 23.1 ± 3.8 points (2–58) and that after treatment (re-examination) 7.8 ± 3.7 points (0–52), p < 0.01. Global histological efficacy (n = 17) results were as follows: none (23.6%), poor (0%), moderate (5.8%), good (35.3%) and excellent (35.3%). Conclusions: Gestrinone is presented as a drug with an efficacy comparable to other pharmacological agents currently available in the medical treatment of endometriosis. Adequate posology and acceptable effectiveness were also observed.

Clinical efficacy

10.1159/000291852

Cite

Citations (4)